抗血管生成治疗联合免疫检查点抑制剂在实体瘤治疗中的研究进展

免疫检查点抑制剂是近年来肿瘤治疗领域的热点，虽然在多种肿瘤中取得了显著的疗效，但仍存在原发耐药与继发耐药的问题。为了进一步提高免疫检查点抑制剂的疗效、克服耐药问题，目前基于免疫微环境调控机制的多项研究将抗血管生成药物与免疫检查点抑制剂联合进行深入的探索。抗血管生成药物联合免疫治疗在多种实体瘤中表现出显著的疗效和生存获益。其中抗血管生成治疗使血管正常化的同时重塑肿瘤免疫微环境，免疫检查点抑制剂不仅通过阻断负性免疫调节信号，增强宿主抗肿瘤免疫反应，而且可以促进血管正常化。本文对抗血管生成药物联合免疫检查点抑制剂治疗实体瘤的相关基础及临床研究文献进行综述。 

Research progress on antiangiogenic therapy combined with immune checkpoint inhibitors for solid tumors

In recent years,immunotherapy has become a hot spot in the field of tumor therapy.Immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy in treating various tumors.However,primary and secondary resistances to immune checkpoint inhibitors are considerable clinical problems.To further improve the efficacy of ICIs and overcome drug resistance,their combined use with angiogenic drugs has been explored in several studies based on the regulatory mechanism of the immune microenvironment.Antiangiogenic drugs combined with immunotherapy have shown significant efficacy and survival benefits in multiple solid tumors.Antiangiogenic therapy remodels the immune microenvironment while normalizing blood vessels.ICIs enhance a host’s anti-tumor immune response by blocking negative immunomodulatory signals and promote vascular normalization.This study reviews basic and clinical research studies of antiangiogenic drugs combined with ICIs for treating solid tumors.